Adjuvant Therapy and The Cytotoxic Effects in Colorectal Cancers
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Therapy".
Deadline for manuscript submissions: 31 May 2026 | Viewed by 5
Special Issue Editor
Special Issue Information
Dear Colleagues,
Recent advances optimizing drug combination strategies and scheduling have significantly improved progression-free survival for metastatic CRC (mCRC) patients, while refinement in patient selection has improved the precision of adjuvant chemotherapy for CRC patients with localized disease. However, advances in chemotherapy for mCRC that improve long-term survival remain an unmet challenge, and the rate of recurrence in CRC patients with localized disease remains unacceptably high. New approaches targeting KRas, BRAF, EGFR, and other established targets in CRC show promise for continued therapeutic development, while continued research seeks to develop new treatments that target pathways important for CRC cancer initiation and progression, such as TGF-b and Wnt, and to increase the applicability and response to immune checkpoint blockade therapy.
The current Special Issue will focus on original research articles and comprehensive reviews illuminating the most recent advances in chemotherapy for CRC both in an adjuvant setting and for treatment of metastatic disease. Studies identifying or validating novel pathways or targets for improved CRC treatment are of special interest. Innovative approaches to using chemotherapy in combination with immunotherapy are of special interest.
Prof. Dr. William H. Gmeiner
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- colorectal cancer
- adjuvant chemotherapy
- targeted therapy
- immunotherapy
- metastatic colorectal cancer
- drug resistance
- combination therapy
- cytotoxic effects
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
